Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 386

1.

Hemostatic abnormalities in patients with ehlers-danlos syndrome.

Artoni A, Bassotti A, Abbattista M, Marinelli B, Lecchi A, Gianniello F, Clerici M, Bucciarelli P, La Marca S, Peyvandi F, Martinelli I.

J Thromb Haemost. 2018 Oct 12. doi: 10.1111/jth.14310. [Epub ahead of print]

PMID:
30312027
2.

Advances in the Treatment of Hemophilia: Implications for Laboratory Testing.

Tripodi A, Chantarangkul V, Novembrino C, Peyvandi F.

Clin Chem. 2018 Oct 3. pii: clinchem.2017.284356. doi: 10.1373/clinchem.2017.284356. [Epub ahead of print] Review.

PMID:
30282700
3.

Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura.

Roose E, Vidarsson G, Kangro K, Verhagen OJHM, Mancini I, Desender L, Pareyn I, Vandeputte N, Vandenbulcke A, Vendramin C, Schelpe AS, Voorberg J, Azerad MA, Gilardin L, Scully M, Dierickx D, Deckmyn H, De Meyer SF, Peyvandi F, Vanhoorelbeke K.

Thromb Haemost. 2018 Oct;118(10):1729-1742. doi: 10.1055/s-0038-1669459. Epub 2018 Sep 20.

PMID:
30235483
4.

Targeted sequencing to identify novel genetic risk factors for deep vein thrombosis: a study of 734 genes.

de Haan HG, van Hylckama Vlieg A, Lotta LA, Gorski MM, Bucciarelli P, Martinelli I, Baglin TP, Peyvandi F, Rosendaal FR; INVENT consortium.

J Thromb Haemost. 2018 Aug 31. doi: 10.1111/jth.14279. [Epub ahead of print]

PMID:
30168256
5.

Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controls.

Mannucci PM, Nobili A, Marchesini E, Oliovecchio E, Cortesi L, Coppola A, Santagostino E, Radossi P, Castaman G, Valdrè L, Santoro C, Tagliaferri A, Ettorre C, Zanon E, Barillari G, Cantori I, Caimi TM, Sottilotta G, Peyvandi F, Iorio A.

Haemophilia. 2018 Sep;24(5):726-732. doi: 10.1111/hae.13595. Epub 2018 Aug 16.

PMID:
30112863
6.

Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis.

Bergmeier W, Antoniak S, Conway EM, Denis CV, George LA, Isermann B, Key NS, Krishnaswamy S, Lam WA, Lillicrap D, Liu J, Looney MR, López JA, Maas C, Peyvandi F, Ruf W, Sood AK, Versteeg HH, Wolberg AS, Wong PC, Wood JP, Weiler H.

Res Pract Thromb Haemost. 2018 Apr 12;2(3):407-428. doi: 10.1002/rth2.12095. eCollection 2018 Jul. Review.

7.

Product type and other environmental risk factors for inhibitor development in severe hemophilia A.

Peyvandi F, Garagiola I.

Res Pract Thromb Haemost. 2018 Apr 10;2(2):220-227. doi: 10.1002/rth2.12094. eCollection 2018 Apr.

8.

Differential diagnosis between type 2A and 2B von Willebrand disease in a child with a previously undescribed de novo mutation.

Pagliari MT, Baronciani L, Stufano F, Colpani P, Siboni SM, Peyvandi F.

Haemophilia. 2018 Jul;24(4):e263-e266. doi: 10.1111/hae.13532. Epub 2018 Jul 25. No abstract available.

PMID:
30044032
9.

Next-generation DNA sequencing to identify novel genetic risk factors for cerebral vein thrombosis.

Gorski MM, de Haan HG, Mancini I, Lotta LA, Bucciarelli P, Passamonti SM, Cairo A, Pappalardo E, van Hylckama Vlieg A, Martinelli I, Rosendaal FR, Peyvandi F.

Thromb Res. 2018 Sep;169:76-81. doi: 10.1016/j.thromres.2018.06.011. Epub 2018 Jun 15.

PMID:
30029070
10.

How and when to measure anticoagulant effects of direct oral anticoagulants? Practical issues.

Tripodi A, Braham S, Scimeca B, Moia M, Peyvandi F.

Pol Arch Intern Med. 2018 Jun 29;128(6):379-385. doi: 10.20452/pamw.4287. Epub 2018 Jun 29.

11.

Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome.

Stufano F, Boscarino M, Bucciarelli P, Baronciani L, Maino A, Cozzi G, Peyvandi F.

Semin Thromb Hemost. 2018 Jun 18. doi: 10.1055/s-0038-1660481. [Epub ahead of print]

PMID:
29913537
12.

An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS-VWF study.

Szederjesi A, Baronciani L, Budde U, Castaman G, Lawrie AS, Liu Y, Montgomery R, Peyvandi F, Schneppenheim R, Várkonyi A, Patzke J, Bodó I.

J Thromb Haemost. 2018 Jun 13. doi: 10.1111/jth.14206. [Epub ahead of print]

PMID:
29897666
13.

Risk factors for inhibitor development in severe hemophilia a.

Garagiola I, Palla R, Peyvandi F.

Thromb Res. 2018 Aug;168:20-27. doi: 10.1016/j.thromres.2018.05.027. Epub 2018 May 25. Review.

PMID:
29879570
14.

Choices of factor VIII products in previously untreated patients with haemophilia A: A global survey.

Peyvandi F, Palla R, Franchi C, Nobili A, Rosendaal FR, Mannucci PM.

Haemophilia. 2018 Jul;24(4):e266-e268. doi: 10.1111/hae.13535. Epub 2018 Jun 5. No abstract available.

PMID:
29869363
15.

Recombinant factor XIII A-subunit in a patient with factor XIII deficiency and recurrent pregnancy loss.

Al-Khabori M, Pathare A, Menegatti M, Peyvandi F.

J Thromb Haemost. 2018 Jun;16(6):1052-1054. doi: 10.1111/jth.14126. Epub 2018 May 13.

PMID:
29665207
16.

Use of oral anticoagulant drugs in older patients with atrial fibrillation in internal medicine wards.

Proietti M, Antoniazzi S, Monzani V, Santalucia P, Franchi C; SIM-AF Investigators, Fenoglio LM, Melchio R, Fabris F, Sartori MT, Manfredini R, De Giorgi A, Fabbian F, Biolo G, Zanetti M, Altamura N, Sabbà C, Suppressa P, Bandiera F, Usai C, Murialdo G, Fezza F, Marra A, Castelli F, Cattaneo F, Beccati V, di Minno G, Tufano A, Contaldi P, Lupattelli G, Bianconi V, Cappellini D, Hu C, Minonzio F, Fargion S, Burdick L, Francione P, Peyvandi F, Rossio R, Colombo G, Monzani V, Ceriani G, Lucchi T, Brignolo B, Manfellotto D, Caridi I, Corazza GR, Miceli E, Padula D, Fraternale G, Guasti L, Squizzato A, Maresca A, Liberato NL, Tognin T, Rozzini R, Bellucci FB, Muscaritoli M, Molfino A, Petrillo E, Dore M, Mete F, Gino M, Franceschi F, Gabrielli M, Perticone F, Perticone M, Bertolotti M, Mussi C, Borghi C, Strocchi E, Durazzo M, Fornengo P, Dallegri F, Ottonello LC, Salam K, Caserza L, Barbagallo M, Di Bella G, Annoni G, Bruni AA, Odetti P, Nencioni A, Monacelli F, Napolitano A, Brucato A, Valenti A, Castellino P, Zanoli L, Mazzeo M.

Eur J Intern Med. 2018 Jun;52:e12-e14. doi: 10.1016/j.ejim.2018.04.006. Epub 2018 Apr 12. No abstract available.

PMID:
29657108
17.

"In vitro" correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate.

Bulato C, Novembrino C, Anzoletti MB, Spiezia L, Gavasso S, Berbenni C, Tagariello G, Farina C, Nardini I, Campello E, Peyvandi F, Simioni P.

Haemophilia. 2018 Jul;24(4):648-656. doi: 10.1111/hae.13465. Epub 2018 Mar 26.

PMID:
29578313
18.

An unusual diagnosis in a 31-year-old man with abdominal pain and hyponatremia.

Depetri F, Cugno M, Graziadei G, Di Pierro E, Granata F, Peyvandi F, Cappellini MD.

Intern Emerg Med. 2018 Mar 17. doi: 10.1007/s11739-018-1826-x. [Epub ahead of print] No abstract available.

PMID:
29550908
19.

First-year results of an expanded humanitarian aid programme for haemophilia in resource-constrained countries.

Pierce GF, Haffar A, Ampartzidis G, Peyvandi F, Diop S, El-Ekiaby M, van den Berg HM.

Haemophilia. 2018 Mar;24(2):229-235. doi: 10.1111/hae.13409. Epub 2018 Mar 14.

PMID:
29537123
20.

Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban.

Martinelli I, Abbattista M, Bucciarelli P, Tripodi A, Artoni A, Gianniello F, Novembrino C, Peyvandi F.

Haematologica. 2018 Jul;103(7):e315-e317. doi: 10.3324/haematol.2017.185132. Epub 2018 Mar 8. No abstract available.

21.

Acquired thrombotic thrombocytopenic purpura in a child: rituximab to prevent relapse. A pediatric report and literature review.

Mariani S, Trisolini SM, Capria S, Moleti ML, Chisini M, Ferrazza G, Bafti MS, Limongiello MA, Miulli E, Peyvandi F, Foà R, Testi AM.

Haematologica. 2018 Mar;103(3):e138-e140. doi: 10.3324/haematol.2017.185363. No abstract available.

22.

Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement.

Spena S, Garagiola I, Cannavò A, Mortarino M, Mannucci PM, Rosendaal FR, Peyvandi F; SIPPET Study Group.

J Thromb Haemost. 2018 Apr;16(4):778-790. doi: 10.1111/jth.13961. Epub 2018 Mar 23.

PMID:
29399993
23.

Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis".

Messori A, Peyvandi F, Trippoli S, Palla R, Rosendaal FR, Mannucci PM.

Blood Transfus. 2017 Dec 22:1. doi: 10.2450/2017.0253-17. [Epub ahead of print] No abstract available.

24.

Idelalisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia.

Reda G, Cassin R, Artoni A, Fattizzo B, Lecchi A, La Marca S, Bucciarelli P, Levati GV, Peyvandi F, Cortelezzi A.

Br J Haematol. 2018 Jan 7. doi: 10.1111/bjh.15052. [Epub ahead of print] No abstract available.

PMID:
29315493
25.

Acquired Von Willebrand syndrome and response to desmopressin.

Biguzzi E, Siboni SM, Peyvandi F.

Haemophilia. 2018 Jan;24(1):e25-e28. doi: 10.1111/hae.13382. Epub 2017 Dec 13. No abstract available.

PMID:
29239101
26.

Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency.

Ross C, Rangarajan S, Karimi M, Toogeh G, Apte S, Lissitchkov T, Acharya S, Manco-Johnson MJ, Srivastava A, Brand B, Schwartz BA, Knaub S, Peyvandi F.

J Thromb Haemost. 2018 Feb;16(2):253-261. doi: 10.1111/jth.13923. Epub 2018 Jan 22.

27.

Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial.

Lissitchkov T, Madan B, Djambas Khayat C, Zozulya N, Ross C, Karimi M, Kavakli K, De Angulo GR, Almomen A, Schwartz BA, Solomon C, Knaub S, Peyvandi F.

Transfusion. 2018 Feb;58(2):413-422. doi: 10.1111/trf.14421. Epub 2017 Nov 30.

PMID:
29194665
28.

Persistent and severe hypoglycemia associated with trimethoprim-sulfamethoxazole in a frail diabetic man on polypharmacy: A case report and literature review
.

Rossio R, Arcudi S, Peyvandi F, Piconi S.

Int J Clin Pharmacol Ther. 2018 Feb;56(2):86-89. doi: 10.5414/CP203084. Review.

PMID:
29191263
29.

Molecular investigation of 41 patients affected by coagulation factor XI deficiency.

Rimoldi V, Paraboschi EM, Menegatti M, Peyvandi F, Salomon O, Duga S, Asselta R.

Haemophilia. 2018 Mar;24(2):e50-e55. doi: 10.1111/hae.13378. Epub 2017 Nov 27. No abstract available.

PMID:
29178608
30.

Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity.

Donadon I, McVey JH, Garagiola I, Branchini A, Mortarino M, Peyvandi F, Bernardi F, Pinotti M.

Haematologica. 2018 Feb;103(2):344-350. doi: 10.3324/haematol.2017.178327. Epub 2017 Nov 23.

31.

A comparative evaluation of a new fully automated assay for von Willebrand factor collagen binding activity to an established method.

Stufano F, Baronciani L, Mane-Padros D, Cozzi G, Faraudo S, Peyvandi F.

Haemophilia. 2018 Jan;24(1):156-161. doi: 10.1111/hae.13371. Epub 2017 Nov 22.

PMID:
29168270
32.

Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio as Risk Factors for Venous Thrombosis.

Artoni A, Abbattista M, Bucciarelli P, Gianniello F, Scalambrino E, Pappalardo E, Peyvandi F, Martinelli I.

Clin Appl Thromb Hemost. 2018 Jul;24(5):808-814. doi: 10.1177/1076029617733039. Epub 2017 Oct 31.

PMID:
29088921
33.

Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.

Peyvandi F, Cannavò A, Garagiola I, Palla R, Mannucci PM, Rosendaal FR; sippet study group.

J Thromb Haemost. 2018 Jan;16(1):39-43. doi: 10.1111/jth.13888. Epub 2017 Nov 16.

34.

The ISTH Bleeding Assessment Tool and the risk of future bleeding.

Fasulo MR, Biguzzi E, Abbattista M, Stufano F, Pagliari MT, Mancini I, Gorski MM, Cannavò A, Corgiolu M, Peyvandi F, Rosendaal FR.

J Thromb Haemost. 2018 Jan;16(1):125-130. doi: 10.1111/jth.13883. Epub 2017 Nov 23.

PMID:
29064634
35.

Factor XIII deficiency diagnosis: Challenges and tools.

Karimi M, Peyvandi F, Naderi M, Shapiro A.

Int J Lab Hematol. 2018 Feb;40(1):3-11. doi: 10.1111/ijlh.12756. Epub 2017 Oct 13. Review.

36.

Minimal factor XIII activity level to prevent major spontaneous bleeds: reply.

Menegatti M, Palla R, Bucciarelli P, Peyvandi F.

J Thromb Haemost. 2017 Nov;15(11):2280-2282. doi: 10.1111/jth.13851. Epub 2017 Oct 9. No abstract available.

PMID:
28926188
37.

9th BIC International Conference: Rome (Italy), 15-17 September 2017.

Mannucci PM, Peyvandi F, Federici AB, Ciavarella N.

Blood Transfus. 2017 Sep 12;15(Supplement no. 3):s475-s518. doi: 10.2450/2017.s3. No abstract available.

38.

Ageing successfully with haemophilia: A multidisciplinary programme.

Boccalandro E, Mancuso ME, Riva S, Pisaniello DM, Ronchetti F, Santagostino E, Peyvandi F, Solimeno LP, Mannucci PM, Pasta G.

Haemophilia. 2018 Jan;24(1):57-62. doi: 10.1111/hae.13308. Epub 2017 Aug 6.

PMID:
28780767
39.

Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis.

Rosendaal FR, Palla R, Garagiola I, Mannucci PM, Peyvandi F; SIPPET Study Group.

Blood. 2017 Oct 12;130(15):1757-1759. doi: 10.1182/blood-2017-06-791756. Epub 2017 Aug 2.

40.

Minimal dataset for post-registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH.

Peyvandi F, Makris M, Collins P, Lillicrap D, Pipe SW, Iorio A, Rosendaal FR; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders.

J Thromb Haemost. 2017 Sep;15(9):1878-1881. doi: 10.1111/jth.13762. Epub 2017 Aug 2. No abstract available.

PMID:
28767195
41.

Potential misdiagnosis of dysfibrinogenaemia: Data from multicentre studies amongst UK NEQAS and PRO-RBDD project laboratories.

Jennings I, Kitchen S, Menegatti M, Palla R, Walker I, Peyvandi F, Makris M.

Int J Lab Hematol. 2017 Dec;39(6):653-662. doi: 10.1111/ijlh.12721. Epub 2017 Aug 2.

PMID:
28766854
42.

Appropriateness of antiplatelet therapy for primary and secondary cardio- and cerebrovascular prevention in acutely hospitalized older people.

Ardoino I, Rossio R, Di Blanca D, Nobili A, Pasina L, Mannucci PM, Peyvandi F, Franchi C; REPOSI Investigators.

Br J Clin Pharmacol. 2017 Nov;83(11):2528-2540. doi: 10.1111/bcp.13355. Epub 2017 Aug 1.

PMID:
28722184
43.

Minimal factor XIII activity level to prevent major spontaneous bleeds.

Menegatti M, Palla R, Boscarino M, Bucciarelli P, Muszbek L, Katona E, Makris M, Peyvandi F; PRO-RBDD study group.

J Thromb Haemost. 2017 Sep;15(9):1728-1736. doi: 10.1111/jth.13772. Epub 2017 Aug 17.

44.

Diagnosis and management of patients with von Willebrand's disease in Italy: an Expert Meeting Report.

Peyvandi F.

Blood Transfus. 2018 Jul;16(4):326-328. doi: 10.2450/2017.0131-17. Epub 2017 May 26. No abstract available.

45.

High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis.

Messori A, Peyvandi F, Trippoli S, Palla R, Rosendaal FR, Mannucci PM.

Blood Transfus. 2018 Feb;16(2):215-220. doi: 10.2450/2017.0352-16. Epub 2017 May 15. No abstract available.

46.

Exploring the global landscape of genetic variation in coagulation factor XI deficiency.

Asselta R, Paraboschi EM, Rimoldi V, Menegatti M, Peyvandi F, Salomon O, Duga S.

Blood. 2017 Jul 27;130(4):e1-e6. doi: 10.1182/blood-2017-04-780148. Epub 2017 Jun 14.

47.

Involvement of the IgE-basophil system and mild complement activation in haemophilia B with anti-factor IX neutralizing antibodies and anaphylaxis.

Cugno M, Mancuso ME, Tedeschi A, Santagostino E, Lorini M, Carbonelli V, Peyvandi F, Mannucci PM.

Haemophilia. 2017 Jul;23(4):e348-e353. doi: 10.1111/hae.13282. Epub 2017 Jun 8.

PMID:
28594432
48.

Genome editing of factor X in zebrafish reveals unexpected tolerance of severe defects in the common pathway.

Hu Z, Liu Y, Huarng MC, Menegatti M, Reyon D, Rost MS, Norris ZG, Richter CE, Stapleton AN, Chi NC, Peyvandi F, Joung JK, Shavit JA.

Blood. 2017 Aug 3;130(5):666-676. doi: 10.1182/blood-2017-02-765206. Epub 2017 Jun 2.

49.

Polypharmacy in older adults with severe haemophilia.

Riva S, Mancuso ME, Cortesi L, Nobili A, Santagostino E, Peyvandi F, Mannucci PM.

Haemophilia. 2018 Jan;24(1):e1-e3. doi: 10.1111/hae.13262. Epub 2017 May 24. No abstract available.

PMID:
28544483
50.

Pregnancy outcome after a first episode of cerebral vein thrombosis: reply.

Martinelli I, Abbattista M, Somigliana E, Gianniello F, Peyvandi F.

J Thromb Haemost. 2017 Jul;15(7):1526. doi: 10.1111/jth.13731. Epub 2017 Jun 4. No abstract available.

PMID:
28457015

Supplemental Content

Loading ...
Support Center